Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  ARTIFICIAL ORGANS
A Global Strategic Business Report

This report analyzes the worldwide markets for Artificial Organs in US$ Million. The major product segments analyzed are Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. Annual forecasts are provided for the period of 2003 through 2015. The report profiles 55 companies including many key and niche players worldwide such as Abbott Laboratories, Abiomed Inc., Arbios Systems, Inc., Asahi Kasei Kuraray Medical Co., Ltd., Baxter International, Inc., F. Hoffmann-La Roche Ltd.., Fresenius Medical Care AG & Co. KGaA, Fresenius Medical Care North America, Inc., Fresenius Kawasumi, Gambro AB, HepaLife Technologies, Inc., Jarvik Heart, Inc., MC3, Inc., Medtronic, Inc., MicroMed Cardiovascular, Inc., Nikkiso Co., Ltd., Nipro Corporation, SynCardia Systems, Inc., Terumo Corporation, Thoratec Corporation, Toray Medical Co., Ltd., Ventracor Limited, Vital Therapies, Inc., WorldHeart Corporation, and Xenogenics Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1126  PAGES:    270
PRICE:    $3950  DATE:       May 2008
COMPANIES:  55  MARKET DATA TABLES:   121
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  ARTIFICIAL ORGANS (Complete Report) Pages : 270   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Artificial Organs.....I-3
Artificial Heart.....I-3
  
   Artificial Kidneys.....I-4
Artificial Liver.....I-4
Artificial Pancreas.....I-4
Artificial Lungs.....I-4
  
II. EXECUTIVE SUMMARY95$3000
  1. Industry Overview.....II-15 $600  
   Artificial Organs Revolutionize Medical Technology Industry.....II-1
Current and Future Analysis.....II-1
1$100
   Market Outlook.....II-2
Opportunities Abound for Bioartificial Organs.....II-2
1$100
   Bionics to Play Crucial Role.....II-3
Economic Situation Plays a Pivotal Role in ESRD Treatment Accessibility.....II-3
1$100
   Table 1: Number of Dialysis Patients by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World for the Year 2006 (includes corresponding Graph/Chart).....II-4
Growth Drivers.....II-4
1$400
   Growth Inhibitors.....II-5
1$100
  2. Market Trends and Issues.....II-64 $400  
   Higher Development Costs and Lengthy Regulatory Process – Stumbling Blocks for Product
  Commercialization.....II-6
Lack of Requisite Expertise – Hindering Implantation Process.....II-6
Alliances to Play a Key Role.....II-6
Aging Population – A Boosting Factor.....II-6
Anemia - A Growing Concern among Renal Failure Patients.....II-6
1$100
   Swelling ESRD Patient Population Spurs Dialyzers Growth.....II-7
Growing Need for Efficient Control and Easy Usage.....II-7
Expiry of Warranty Provides New Opportunities.....II-7
Xenotransplantation – Other Alternative to Donor Organ Shortage.....II-7
Artificial Organs from Cloned Animal Cells – A Promising Trend.....II-7
1$100
   Immunosuppressants Hold Promise in Artificial Organs Market.....II-8
Move Towards Smaller Implantable Devices.....II-8
Barriers to Entry Significantly High in Dialyzers Market.....II-8
Reuse of Dialyzers – A Major Issue in Dialysis Industry.....II-8
Poor Reimbursement Environment Stymies Innovation.....II-8
1$100
   Pricing Trends in Artificial Organs.....II-9
1$100
  3. Competitive Scenario.....II-107 $1100  
   Competition Heating Up in Artificial Pancreas Domain.....II-10
Fresenius Medical Care – Leads the Worldwide Dialysis Equipment and Supplies
  Market.....II-10
1$100
   Table 2: Leading Players in the Worldwide Dialysis Equipment and Supplies Market (2006) – Percentage Breakdown of Sales for Fresenius Medical Care ,Baxter, Gambro and Others (includes corresponding Graph/Chart).....II-11

Table 3: Leading Players in the Worldwide Hemodialysis Equipment and Supplies Market (2006) – Percentage Breakdown of Sales for Fresenius Medical Care, Gambro, Baxter and Others (includes corresponding Graph/Chart).....II-11

Table 4: Leading Players in the Worldwide Peritoneal Dialysis Equipment and Supplies Market (2006) – Percentage Breakdown of Sales for Baxter, Fresenius Medical Care, Sonstige and Gambro (includes corresponding Graph/Chart).....II-11
Competitive Landscape of Artificial Kidney or Dialyzers Market.....II-11
1$400
   Table 5: Leading Players in the Worldwide Dialyzers Market (2007): Percentage Breakdown of Unit Output for Fresenius Medical Care, Gambro and Others (includes corresponding Graph/Chart).....II-121$400
   Synthetic Dialyzers to Attain Mainstay.....II-13
Asahi Kasei Medical Dominates Japanese Dialyzers Market.....II-13
Table 6: Leading Players in the Japanese Kidney Dialyzers Market (2005 & 2006) – Percentage Breakdown of Sales for Asahi Kasei, Nipro, Kawasumi, Toray and Others (includes corresponding Graph/Chart).....II-13
Competitive Landscape of Ventricular Assist Devices.....II-13
1$400
   Various Ventricle Assist Devices.....II-14
Thoratec – Leads the VADs Market.....II-14
1$100
   Table 7: Leading Players in the Worldwide VADs Market (2005 & 2006) – Percentage Breakdown of Sales for Thoratec, Abiomed, WorldHeart and Others (includes corresponding Graph/Chart).....II-15
Liver Assist Devices Competitive Landscape.....II-15
1$400
   Various Liver Assist Devices.....II-16
Core Competitive Factors.....II-16
1$100
  4. Product Overview.....II-1730 $1500  
   Artificial Organs.....II-17
Categorization of Artificial Organs.....II-17
External Artificial Organs.....II-17
Internal or Implantable Artificial Devices.....II-17
Artificial Heart.....II-17
1$100
   Total Artificial Heart (TAH).....II-18
Ventricle Assist Device (VAD).....II-18
Table 8: Distribution of Various Uses of VADs (includes corresponding Graph/Chart).....II-18
Right Ventricular Assist Systems (RVAS).....II-18
Left Ventricular Assist Systems (LVAS).....II-18
Categorization of LVAS.....II-18
First Generation LVAS.....II-18
1$400
   Second Generation LVAS.....II-19
Third Generation LVAS.....II-19
1$100
   Benefits of LVAS.....II-20
Major Limitations and Complications of VADs.....II-20
1$100
   Infection.....II-21
Internal Bleeding.....II-21
Thrombus.....II-21
Dependability.....II-21
Cost.....II-21
1$100
   Table 9: Average Selling Price per Unit (includes corresponding Graph/Chart).....II-22

Table 10: Distribution of Direct Costs for Heart Failure in the US (2004) (includes corresponding Graph/Chart).....II-22
Natural Human Heart.....II-22
1$400
   Heart Diseases.....II-23
Congenital Heart Disease.....II-23
Congestive Heart Failure.....II-23
Types of Heart Failure.....II-23
Diastolic Heart Failure.....II-23
Systolic Heart Failure.....II-23
Artificial Heart - A Historical Perspective.....II-23
1$100
   Major Milestones in Artificial Heart Development.....II-24
Jarvik-7.....II-24
1$100
   AbioCor Total Artificial Heart.....II-25
Major Advancements in AbioCor Over Jarvik-7.....II-25
1$100
   CardioWest Temporary Total Artificial Heart.....II-26
DuraHeart LVAS.....II-26
1$100
   HeartSaverVAD.....II-27
VentrAssist Left Ventricular Assist Device.....II-27
Artificial Kidney (Dialyzer).....II-27
1$100
   Limitations of Artificial Kidney.....II-28
Types of Dialysis.....II-28
Hemodialysis.....II-28
1$100
   Peritoneal Dialysis.....II-29
Advances in Artificial Kidney Technology.....II-29
1$100
   Bioartificial Kidneys.....II-30
Limitations of Bioartificial Kidneys.....II-30
1$100
   Hindrances to Develop Implantable Artificial Kidney.....II-31
Artificial Kidneys - A Historical Perspective.....II-31
Artificial Liver.....II-31
1$100
   Overdose of Drugs – A Leading Cause for Liver Damage.....II-32
Categorization of Liver Devices.....II-32
1$100
   Mechanical Systems.....II-33
Liver Dialysis Unit™.....II-33
Molecular Adsorbents Recirculating System.....II-33
SEPET.....II-33
1$100
   Bio-Artificial Systems.....II-341$100
   Capillary Hollow Fiber Systems.....II-35
Direct Perfusion Systems.....II-35
Entrapment Based Systems.....II-35
1$100
   Major BAL Devices.....II-36
Extracorporeal Liver Assist Device (ELAD).....II-36
Cellular Components.....II-36
Types of Bioreactor.....II-36
HepatAssist-2™ Bioartificial Liver System.....II-36
1$100
   Hybrid Artificial Liver Support System.....II-37
History of Artificial Liver.....II-37
1$100
   Liver Assist Devices – Major Milestones.....II-38
Nonbiological Method Introduction Time Line.....II-38
Biological Method Introduction Time Line.....II-38
Artificial Pancreas.....II-38
1$100
   Insulin Pumps - Historical Perspective.....II-391$100
   Bioartificial Pancreas.....II-40
Nanotechnology in Artificial Pancreas.....II-40
1$100
   Medtronic Minimed, Inc Products.....II-41
External Artificial Pancreas.....II-41
Implantable Artificial Pancreas.....II-41
MiniMed Paradigm® REAL-Time Insulin Pump and CGM System.....II-41
Guardian® RT CGM System.....II-41
Abbott Products.....II-41
FreeStyle Navigator CGM System.....II-41
1$100
   CozMore Insulin Technology System.....II-42
Artificial Lungs (Oxygenator).....II-42
About Human Lungs.....II-42
Types of Artificial Lung.....II-42
1$100
   Intravenous Membrane Oxygenator.....II-43
Hattler Respiratory Catheter.....II-43
MC3 Pulmonary Assist Device.....II-43
In-Series.....II-43
In-Parallel.....II-43
BioLung.....II-43
1$100
   Heart-Lung Bypass Machine.....II-44
Role of Artificial Lungs during Surgery.....II-44
Direct Contact Device.....II-44
Indirect-Contact Type-Membrane Devices.....II-44
1$100
   Biorubber to be used in Artificial Lungs.....II-45
History of Artificial Lungs.....II-45
An Overview of Tissue Engineering.....II-45
2$200
  5. Introduction to Biomaterials.....II-471 $100  
   Introduction to Biomaterials.....II-47
1$100
  6. Organ Transplantation.....II-487 $1400  
   Sources of Donor Organs.....II-48
Table 11: US Recent Past, Current & Future Analysis for Kidney Transplant Donations by Donor Type - Cadaveric and Living in Units for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-48
1$400
   Table 12: US Historic Review for Kidney Transplant Donations by Donor Type - Cadaveric and Living in Units for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-49

Table 13: US Recent Past, Current & Future Analysis for Liver Transplant Donations by Donor Type - Cadaveric and Living in Units for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-49

Table 14: US Historic Review for Liver Transplant Donations by Donor Type - Cadaveric and Living in Units for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-49
1$400
   Table 15: US Recent Past, Current & Future Analysis for Heart Transplants -Donations by Cadaveric Donor Type in Units for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-50

Table 16: US Historic Review for Heart Transplant Donations by Donor Type - Cadaveric and Living in Units for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-50

Table 17: US Recent Past, Current & Future Analysis for Pancreatic Transplant Donations by Donor Type - Cadaveric and Living in Units for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-50
1$400
   Major Milestones in Organ Transplantation.....II-51
US Organ Transplant Facts.....II-51
Shortage of Donor Organs Restricts Transplantation Procedures.....II-51
1$100
   Table 18: Survival Percentage of Transplanted Organs (includes corresponding Graph/Chart).....II-521$400
   Table 19: Waiting List of Patients in the US as of July 2007 (includes corresponding Graph/Chart).....II-53

Table 20: Waiting List of Active and Inactive Patients in the US for Years 2004 & 2005 (includes corresponding Graph/Chart).....II-53
Organ Rejection – A Major Barrier to Transplantation.....II-53
1$400
   Other Issues for Organ Transplantation.....II-54
Combined Organ Transplantation – Gaining Attention.....II-54
1$100
  7. Regulatory Environment.....II-552 $200  
   Regulatory Environment in the US.....II-551$100
   Regulatory Environment in Europe.....II-56
1$100
  8. Product Innovations/Introductions.....II-575 $500  
   Gambro Unveils AK 96™ Dialyzer.....II-57
Nipro Introduces Artificial Kidney Dialyzer in Overseas Markets.....II-57
University of Michigan Develops Artificial Lungs.....II-57
USC Researchers Develop Argus II Retinal Prosthesis System for Retinal Implant.....II-57
1$100
   Researchers Develop Cell Manipulation Technique for Organ Regeneration Process.....II-58
Terumo to Introduce First CE Mark LVAS in Europe.....II-58
Advanced Technique for Nerve Re-Growth Developed.....II-58
JDRF Develops Artificial Pancreas.....II-58
1$100
   Direct Attachment of Artificial Limbs Technique Developed.....II-59
Artificial Pancreas to Generate Hope for Young Diabetics.....II-59
Artificial Liver Developed Using Stem Cells.....II-59
Artificial Liver Device from HepaLife.....II-59
1$100
   Researchers Develop Human Nephron Filter.....II-60
Ventracor Completes Pilot Trial of VentrAssist.....II-60
National Cardiovascular Center Develops Completely Implantable Wireless Artificial
  Heart.....II-60
1$100
   InnovaMedica Reveals Prototype for Economical Artificial Heart.....II-61
Researchers Develop Membrane-Based Microscopic Device.....II-61
1$100
  9. Recent Industry Activity.....II-6217 $1000  
   Thoratec Receives FDA Approval for HeartMate II® .....II-62
Asahi Kasei Institutes a Sales Subsidiary in Taiwan.....II-62
Arbios Seeks CE Marking for SEPET™.....II-62
Gambro Teams up with Debiotech for Developing Peritoneal Dialysis Cycler.....II-62
1$100
   Arbios Obtains US FDA Approval for Initiating Clinical Trial for SEPET™.....II-63
Abiomed Obtains HDE Supplement Approval from FDA for AbioCor® Implantable Artificial
  Heart.....II-63
Ventracor Obtains CE Marking for VentrAssist™ LVAD.....II-63
Fresenius Medical Care Takes Over Renal Solutions, Inc......II-63
Arbios Inks Exclusive Agreement with NxStage for SEPET™.....II-63
1$100
   WorldHeart Completes First Multi-Day Animal Study of PediaFlow™ VAD.....II-64
Xcorporeal, Inc. Completes Merger with CT Holdings.....II-64
Nikkiso Collaborates with Nipro for Overseas Launch of its Dialysis Systems.....II-64
Ege University to Initiate Artificial Heart Project.....II-64
Vascutek Buys Kohler Chemie’s Heart Valve Business.....II-64
NovaThera Partners with NovaLung to Develop Advanced Artificial Lung.....II-64
1$100
   Aksys Quits Kidney Dialysis Machines Business.....II-65
Twardowski Terminates License Agreement with Aksys.....II-65
Asahi Kasei Medical Fortifies Competence in Artificial Kidney Production.....II-65
Fresenius Medical Care Enhances Dialyzer Output.....II-65
HepaLife Appoints Stem Cell Systems for Bioreactor Development.....II-65
Hanger Orthopedic Acquires Regional Artificial Limb & Brace.....II-65
1$100
   Gambro Acquires Hemapure.....II-66
Fresenius Medical Care Snaps Up Renal Care Group.....II-66
CLSI Teams Up with DTS.....II-66
Abiomed to Foray into the Indian Market.....II-66
Asahi Kasei Medical to Double Artificial Kidney Production in China.....II-66
Thoratec Bags FDA Approval for IDE Supplement for HeartMate II Phase II Trial under
  CAP.....II-66
1$100
   SynCardia Systems Obtains CE Mark to Sell EXCOR® TAH-t Mobile Driver with CardioWest™
  TAH-t in Europe.....II-67
FDA Grants Approval for Medtronic’s Guardian® Real- Time CGM System.....II-67
DexCom Bags FDA Approval for STS Continuous Glucose Monitoring System.....II-67
Vital Therapies Obtains FDA Guidance to Ship ELAD to China.....II-67
1$100
   MC3 Secures Phase I STTR Grant from NHLBI to Develop Pump-Oxygenator.....II-68
Pauley Heart Center Implants First CardioWest TAH-t on East Coast.....II-68
LDS Hospital Team Implants WorldHeart’s New Artificial Heart Device in Greece.....II-68
Novacor LVAS Support Recipient Completes Five Years.....II-68
1$100
   SynCardia Systems to Increase CardioWest TAH-t Transplant Hospitals.....II-69
National Quality Care Divests Dialysis Unit to Kidney Dialysis Center.....II-69
1$100
   Medtronic Gains FDA Approval for Mini Med Paradigm® REAL-Time System.....II-70
MicroMed Receives CE Mark Extension for DeBakey VAD® System.....II-70
Thoratec Files Data On HeartMate II LVAS for Pre-Market Approval.....II-70
Arbios Systems Receives FDA Allowance to Expand Eligibility Criteria for SEPET™ Liver
  Assist Device.....II-70
1$100
   Abiomed’s AbioCor® Artificial Heart Receives FDA Approval.....II-71
Abiomed’s IMPELLA 5.0 Receives Conditional IDE Approval.....II-71
1$100
   WorldHeart Makes Synergistic Purchase of MedQuest.....II-72
Nipro Takes Over Artificial Lung Business from Dainippon Ink and Chemicals.....II-72
Baxter Inks Pact with Gambro Renal Products.....II-72
Xenogenics Bags Patent for Synthetic Bio-Liver Device.....II-72
1$100
   Gambro Bags FDA Approval for MARS for Drug Overdose and Poisoning.....II-73
Einstein Medical Center Participates in Artificial Liver Support Device’s Clinical
  Trail.....II-73
SynCardia Announces First CardioWest TAH-t Implantation at The Cleveland
  Clinic.....II-73
SynCardia Announces Implantation of CardioWest™ TAH-t for Destination Therapy in
  Germany.....II-73
Australian Patients Receive Jarvik 2000.....II-73
1$100
   WorldHeart Bags Three Patents for Ventricular Assist Pumps.....II-74
Asahi Kasei Medical’s First APS™ Dialyzers Assembly Line Commences Operations.....II-74
Arrow International Halts LionHeart LVAS.....II-74
Arbios Systems Takes Over Circe Biomedical’s Bioartificial Liver Assets.....II-74
Roche Makes a Synergetic Purchase of Disetronic.....II-74
1$100
   MultiCell Technologies Merges with Exten Industries.....II-75
HepaLife Technologies Expands Cooperative Research Agreement Scope.....II-75
MedQuest Wins Contract from NIH to Develop LVAD for Infants.....II-75
Jarvik Heart Receives Contract from NIH to Develop VADs for Children.....II-75
SynCardia Receives FDA Approval for CardioWest™ Temporary Total Artificial
  Heart.....II-75
1$100
   FDA Grants Approval for SynCardia Systems’ Partial Artificial Heart.....II-76
Thoratec Obtains FDA approval for Implantable Ventricular Assist Device.....II-76
FDA Grants Approval to World Heart’s Novacor® LVAS for Destination Therapy.....II-76
1$100
   MicroMed Technology Receives Approval for DeBakey VAD Child Heart Pump.....II-77
FDA Awards Orphan Drug Designation for Core Component of Vital Therapies’ ELAD.....II-77
SynCardia Systems Licenses Technology from MEDOS.....II-77
MicroMed Technology Announces Implantation of First DeBakey VAD for Destination
  Therapy.....II-77
Vital Therapies Takes Over VitaGen Assets.....II-77
1$100
   Advanced Biotherapy Inks Agreement with Russian Federation Ministry of Health/State
  Institute of Transplantation and Artificial Organs.....II-78
Novalung Signs Agreements with MC3.....II-78
1$100
  10. Focus on Select Global Players.....II-799 $500  
   Abbott Laboratories (USA).....II-79
Abiomed Inc (USA).....II-79
Arbios Systems, Inc. (USA).....II-79
1$100
   Asahi Kasei Kuraray Medical Co., Ltd (Japan).....II-80
Baxter International, Inc. (USA).....II-80
F. Hoffmann-La Roche Ltd. (Switzerland).....II-80
1$100
   Fresenius Medical Care AG & Co. KGaA (Germany).....II-81
Fresenius Medical Care North America, Inc......II-81
1$100
   Fresenius Kawasumi (Japan).....II-82
Gambro AB (Sweden).....II-82
HepaLife Technologies, Inc. (USA).....II-82
1$100
   Jarvik Heart, Inc. (USA).....II-83
MC3, Inc. (USA).....II-83
Medtronic, Inc. (USA).....II-83
1$100
   MicroMed Cardiovascular, Inc. (USA).....II-84
Nikkiso Co., Ltd. (Japan).....II-84
Nipro Corporation (Japan).....II-84
1$100
   SynCardia Systems, Inc. (USA).....II-85
Terumo Corporation (Japan).....II-85
Thoratec Corporation (USA).....II-85
1$100
   Toray Medical Co., Ltd. (Japan).....II-86
Ventracor Limited (Australia).....II-86
Vital Therapies, Inc. (USA).....II-86
1$100
   WorldHeart Corporation (USA).....II-87
Xenogenics Corporation (USA).....II-87
1$100
  11. Global Market Perspective.....II-88   
   Table 21: World Recent Past, Current & Future Analysis for Artificial Organs by Product Segment –Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-881$400
   Table 22: World Long-term Projections for Artificial Organs by Product Segment –Artificial Heart, Artificial Kidneys, Artificiasl Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-891$400
   Table 23: World 8-Year Perspective for Artificial Organs by Product Segment – Percentage Breakdown of Dollar Sales for Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-901$400
   Table 24: World Recent Past, Current & Future Analysis for Artificial Kidneys/Dialyzers by Geographic Region - USA, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-911$400
   Table 25: World Long-term Projections for Artificial Kidneys/Dialyzers by Geographic Region - USA, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-921$400
   Table 26: World 8-Year Perspective for Artificial Kidneys/Dialyzers by Geographic Region- Percentage Breakdown of Dollar Sales for USA, Canada, Japan,Europe, Asia–Pacific (excluding Japan), Middle East,and Latin American Markets for Years 2003,2008 & 2012 (includes corresponding Graph/Chart).....II-931$400
   Table 27: World Recent Past, Current & Future Analysis for Insulin Pumps (External) by Geographic Region – USA,Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-94

Table 28: World Long-term Projections for Insulin Pumps (External) by Geographic Region – USA, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-94
1$400
   Table 29: World 8-Year Perspective for Insulin Pumps External) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-951$400
III. COMPETITIVE LANDSCAPE 162$995
  
Total Companies Profiled: 55 (including Divisions/Subsidiaries - 67)

Region/Country                 Players

The United States                 40
Canada                             1
Japan                             10
Europe                            15
     France                        1
     Germany                       6
     The United Kingdom            2
     Italy                         3
     Rest of Europe                3
Asia-Pacific (Excluding Japan)     1
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.